Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

David L Kaplan,1 Brian L Ung,2 Corey Pelletier,2 Chuka Udeze,2 Ibrahim Khilfeh,3 Marc Tian2 1Adult & Pediatric Dermatology, Overland Park, Kansas, USA; 2US HEOR, Celgene Corporation, Summit, New Jersey, USA; 3US HEOR, Amgen Inc, Thousand Oaks, California, USACorrespondence: Corey Pelletier E...

Full description

Bibliographic Details
Main Authors: Kaplan DL, Ung BL, Pelletier C, Udeze C, Khilfeh I, Tian M
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
adherence
apremilast
healthcare costs
il inhibitors
tnf inhibitors
treatment pattern
Online Access:https://www.dovepress.com/switch-rates-and-total-cost-of-care-associated-with-apremilast-and-bio-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/switch-rates-and-total-cost-of-care-associated-with-apremilast-and-bio-peer-reviewed-article-CEOR

Similar Items